On Friday, Astrazeneca plc ADR (NASDAQ: AZN) opened higher 0.38% from the last session, before settling in for the closing price of $71.15. Price fluctuations for AZN have ranged from $60.47 to $87.68 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 16.24% over the last five years. Company’s average yearly earnings per share was noted 12.23% at the time writing. With a float of $3.10 billion, this company’s outstanding shares have now reached $3.10 billion.
The firm has a total of 89900 workers. Let’s measure their productivity. In terms of profitability, gross margin is 78.24%, operating margin of 18.87%, and the pretax margin is 15.8%.
Astrazeneca plc ADR (AZN) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Astrazeneca plc ADR is 0.03%, while institutional ownership is 16.33%.
Astrazeneca plc ADR (AZN) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted 0.87 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 0.84) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to 17.72% growth over the previous five years of trading.
Astrazeneca plc ADR (NASDAQ: AZN) Trading Performance Indicators
Check out the current performance indicators for Astrazeneca plc ADR (AZN). In the past quarter, the stock posted a quick ratio of 0.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.51. Likewise, its price to free cash flow for the trailing twelve months is 22.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.06, a number that is poised to hit 1.02 in the next quarter and is forecasted to reach 4.69 in one year’s time.
Technical Analysis of Astrazeneca plc ADR (AZN)
Analysing the last 5-days average volume posted by the [Astrazeneca plc ADR, AZN], we can find that recorded value of 5.4 million was better than the volume posted last year of 5.02 million. As of the previous 9 days, the stock’s Stochastic %D was 12.00%. Additionally, its Average True Range was 1.22.
During the past 100 days, Astrazeneca plc ADR’s (AZN) raw stochastic average was set at 2.87%, which indicates a significant decrease from 6.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 17.65% in the past 14 days, which was lower than the 17.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $79.15, while its 200-day Moving Average is $74.82. Now, the first resistance to watch is $71.75. This is followed by the second major resistance level at $72.09. The third major resistance level sits at $72.31. If the price goes on to break the first support level at $71.19, it is likely to go to the next support level at $70.97. Now, if the price goes above the second support level, the third support stands at $70.63.
Astrazeneca plc ADR (NASDAQ: AZN) Key Stats
There are currently 3,100,589K shares outstanding in the company with a market cap of 221.44 billion. Presently, the company’s annual sales total 45,811 M according to its annual income of 5,955 M. Last quarter, the company’s sales amounted to 12,938 M and its income totaled 1,927 M.
